DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for rhizomelic chondrodysplasia punctata — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRhizomelic chondrodysplasia punctata maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rhizomelic chondrodysplasia punctata is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
peroxisomal biogenesis factor 5 (PEX5) — PEX5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-hydroxy-ethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4KYO · 2.2 Å · ligand 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL (BTB). Experimental structure, not a prediction.
What the evidence adds up to
Rhizomelic chondrodysplasia punctata is a rare, lethal genopathy with autosomal recessive inheritance, as described in 1971 based on 33 literature cases and 9 personal observations. The radiographic hallmarks are symmetrical severe shortening of femur and/or humerus, pronounced metaphyseal ossification disturbances, epiphyseal and extra-epiphyseal calcification foci in the first year of life with later epiphyseal ossification anomalies, vertical systemic ossification clefts of the vertebral bodies, and trapezoid dysplasia of the iliac wings. Features 1, 2, 4 and 5 are unique to this form and distinguish it from the Conradi-Hünermann type on pathogenetic, prognostic and genetic grounds.
A 2003 case report describes a 52-day-old child with rhizomelic micromelia, characteristic facies, suction difficulty, and anthropometric measures below expected for age. Skeletal radiographs showed humeral and femoral shortening with stippled calcifications at shoulders, hips and knees. The patient also had a heart malformation, described as a less common manifestation. The authors note that only 72 cases had been reported by 1995, that prognosis is bad, and that death usually occurs within the first year. Diagnosis in this case was made on clinical and radiological criteria because the biochemical markers could not be tested.
A 1999 review of prenatal diagnosis states that biochemical or molecular testing is necessary to accurately diagnose the form of RCDP due to alkyldihydroacetonephosphate acyltransferase synthase deficiency. In one family with an affected daughter, post-mortem examination of a terminated fetus showed that radiologic examination alone could not make the diagnosis. No treatment or intervention is discussed in any of these abstracts.
What is still missing: any controlled trial of a drug or dietary intervention, any prospective data on survival beyond the first year in treated versus untreated patients, and any validated biochemical or genetic stratification that might identify a less severe subgroup. The natural history study mentioned in a 2019 conflict-of-interest statement is not yet reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 1971 · 22 citations
Chondrodysplasia punctata (Chondrodystrophia calcificans) II. Der rhizomele Typ<sup>*</sup>
AbstractDie rhizomele Form der Chondrodysplasia punctata ist eine letale, wahrscheinlich autosomal-rezessiv vererbte Genopathie mit folgenden röntgenologischen Merkmalen: 1. Symmetrische, schwere Verkürzung von Femur und/oder Humerus. 2. Ausgeprägte metaphysäre Ossifikationsstörungen. 3. Epiphysäre und extraepiphysäre Verkalkungsherde im ersten Lebensjahr, spätere epiphysäre Ossifikationsanomalien. 4. Vertikale, systemhafte Ossifikationsspalten der Wirbelkörper. 5. Trapezförmige Dysplasie der Beckenschaufeln. Die Merkmale 1, 2, 4 und 5 werden nur bei dieser Form der Chondrodysplasia punctata angetroffen. Ihre Differenzierung von der Conradi-Hünermannschen Form der Chondrodysplasia punctata ist aus pathogenetischen, prognostischen und genetischen Gründen erforderlich. Dem rhizomelen Typ der Chondrodysplasie punctata werden 33 Literaturfälle und 9 eigene Beobachtungen zugeordnet.
American Journal of Medical Genetics Part A · 2019 · 21 citations · open access
Rhizomelic chondrodysplasia punctata morbidity and mortality, an update
AbstractDr. Michael Bober is a PI for A Prospective Natural History Study of Patients with Rhizomelic Chondrodysplasia Punctata, sponsored by Med-Life Discoveries LP. Dr. Michael Bober, Dr. Nancy Braverman, and Dr. Poll-Thé are also members of Medical Advisory Board for RhizoKids International. The other authors have no conflict of interest to declare. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Prenatal diagnosis of rhizomelic chondrodysplasia punctata due to isolated alkyldihydroacetonephosphate acyltransferase synthase deficiency
AbstractCurrent practices in prenatal diagnosis of rhizomelic chondrodysplasia punctata (RCDP) are reviewed. A case is presented with a family having one daughter affected with RCDP due to alkyldihydroacetonephosphate acyltransferase synthase (DHAPAT synthase) deficiency, and three subsequent pregnancies. Biochemical test values are presented for the pregnancies and daughter. Post-mortem tests of one fetus of a terminated pregnancy showed that radiologic examination could not make the diagnosis of RCDP. We conclude that biochemical or molecular testing is necessary to accurately diagnose this type of RCDP prenatally.
Jornal de Pediatria · 2003 · 11 citations · open access
Condrodisplasia puntiforme forma rizomélica: relato de caso
AbstractOBJECTIVE: To report a case of rhizomelic chondrodysplasia punctata and present a brief literature review. DESCRIPTION: The authors report the case of a 52-day-old child presenting the main findings of the syndrome: rhizomelic micromelia, characteristic facies, suction difficulty and anthropometric measures below the expected indexes for his age. Skeletal radiographies showed humeri and femora shortening and calcifications stippling on shoulders, hips and knees joints. The patient also presented heart malformation, a less common manifestation of the syndrome. COMMENTS: The rhizomelic form of chondrodysplasia punctata is rare, with only 72 cases reported until 1995. The prognosis is bad and death usually occurs within the first year of age. The case presented here was diagnosed based on clinical and radiological criteria, due to the impossibility of searching for the peculiar biochemical markers.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
